What are Myelodysplastic Syndromes

Myelodysplastic Syndromes (MDS) are a group of diverse bone marrow disorders where the blood-forming cells do not mature properly, leading to low blood cell counts and an increased risk of developing acute myeloid leukemia. These conditions fundamentally disrupt the body’s ability to produce healthy, functional red blood cells, white blood cells, or platelets, requiring careful medical monitoring and management.

What happens in the body with Myelodysplastic Syndromes?

In patients with Myelodysplastic Syndromes, the bone marrow fails to produce enough healthy blood cells. The immature cells, known as "blasts," often die within the bone marrow before they can enter the bloodstream. This leads to cytopenias—a shortage of one or more types of blood cells. At DiseaseMaps.org, 36 community members have shared their experiences, reflecting the unique challenges of navigating this diagnosis, which affects the hematopoietic system and can lead to fatigue, frequent infections, or bleeding issues.

How are Myelodysplastic Syndromes classified?

The World Health Organization (WHO) classifies Myelodysplastic Syndromes based on the appearance of blood cells under a microscope, the percentage of blast cells, and the presence of specific genetic mutations. Common subtypes include:

• MDS with single or multilineage dysplasia


• MDS with ring sideroblasts


• MDS with excess blasts (MDS-EB-1 and MDS-EB-2)


• MDS with isolated del(5q)

Who is typically affected by Myelodysplastic Syndromes?

Myelodysplastic Syndromes are primarily diseases of aging. The median age of onset is approximately 70 to 75 years old. While rare in children, it can occur in younger adults, often due to genetic predispositions or prior exposure to chemotherapy or radiation. Statistically, the condition has a slight male predominance, and incidence rates are estimated at roughly 4 to 5 cases per 100,000 people annually in the general population, though this increases significantly in those over age 65.

How do Myelodysplastic Syndromes differ from other blood disorders?

Unlike aplastic anemia, where the bone marrow is "empty," Myelodysplastic Syndromes typically feature a "hypercellular" marrow that is busy but ineffective. Furthermore, unlike leukemia, which is characterized by the rapid, uncontrolled growth of malignant cells, Myelodysplastic Syndromes are defined by cell maturation failure, though they are considered a pre-leukemic state.

Next steps

• Consult a hematologist-oncologist specializing in bone marrow failure syndromes.


• Request a bone marrow biopsy and cytogenetic testing to confirm your specific subtype.


• Connect with the 36 members of the DiseaseMaps.org community to share support and resources.


• Ask your physician about clinical trials for novel targeted therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Myelodysplastic syndromes


• Orphanet: Myelodysplastic syndrome


• The Myelodysplastic Syndromes Foundation (mds-foundation.org)


• National Cancer Institute (NCI): PDQ Adult Treatment Editorial Board. Myelodysplastic Syndromes Treatment.